Loading…
Ultragenyx Pharmaceutical Inc. is projected to rise to $26.68 by 2027, a +14% move from its current price of $23.39. RARE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $22.85 | $23.39 | $23.95 | +0.02% |
| May 30 | $22.64 | $23.40 | $24.18 | +0.03% |
| May 31 | $22.47 | $23.40 | $24.37 | +0.05% |
| Jun 1 | $22.34 | $23.41 | $24.53 | +0.07% |
| Jun 2 | $22.22 | $23.41 | $24.67 | +0.08% |
| Jun 3 | $22.11 | $23.41 | $24.79 | +0.10% |
| Jun 4 | $22.01 | $23.42 | $24.91 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $22.01 | $23.42 | $24.91 | +0.12% |
| Week 2 | $21.48 | $23.44 | $25.59 | +0.23% |
| Week 3 | $21.09 | $23.47 | $26.12 | +0.35% |
| Week 4 | $20.77 | $23.50 | $26.59 | +0.47% |
| Week 5 | $20.49 | $23.53 | $27.01 | +0.58% |
| Week 6 | $20.24 | $23.55 | $27.40 | +0.70% |
| Week 7 | $20.02 | $23.58 | $27.77 | +0.82% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases across North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its marketed biologic products include Crysvita (burosumab) for X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii for Mucopolysaccharidosis VII, Dojolvi for long-chain fatty acid oxidation disorders, and Evkeeza (evinacumab) for homozygous familial hypercholesterolemia.
The company was incorporated in 2010 and is headquartered in Novato, California. It participates in a broad set of collaborations with Kyowa Kirin, Saint Louis University, Baylor Research Institute, REGENXBIO, GeneTx, Mereo, University of Pennsylvania, Solid Biosciences, Regeneron, Abeona, and Arcturus Therapeutics Holdings Inc. The portfolio includes Phase 3 candidates such as UX143, UX111, DTX401, DTX301, and GTX-102, along with UX701 in Phase 2 and UX053 for glycogen storage disease type III.
Ultragenyx is a Healthcare sector stock with current price of $23.39 and a market cap of $2.3B. It holds a position outside the top ranks with a market capitalization that places it at rank 1903. These fundamentals sit alongside a set of technicals and a multi-year price forecast that projects continued upside in the years ahead.
The stated price outlook shows a progression from a near-term neutral stance to a longer-term bullish trajectory.
A major floor 20.9% below — a decisive break under it would weaken the trend.
The nearest floor, 4.0% below — buyers have tended to step in here.
The nearest ceiling, 14.7% above — a clean break opens room to run.
A major ceiling 22.3% above — clearing it would confirm fresh momentum.
Key RARE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RARE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $23.40 | Sell | $23.49 | Sell |
| MA 10 | $24.09 | Sell | $23.92 | Sell |
| MA 20 | $24.78 | Sell | $24.25 | Sell |
| MA 50 | $23.40 | Sell | $24.05 | Sell |
| MA 100 | $23.23 | Buy | $24.77 | Sell |
| MA 200 | $27.49 | Sell | $27.41 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.75 | Neutral |
| Stoch RSI (14) | 23.11 | Neutral |
| CCI (20) | -88.01 | Neutral |
| Williams %R (14) | -78.59 | Info |
| MACD (12,26,9) | -0.35 | Sell |
| ROC (12) | -10.45 | Sell |
| Bollinger %B (20,2) | 0.22 | Neutral |
| Stochastic %K (14) | 21.41 | Neutral |
| TRIX (15) | 0.14 | Buy |
| Awesome (5,34) | -1.20 | Sell |
| Ultimate (7,14,28) | 34.52 | Neutral |
| Momentum (10) | -3.45 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 23.10 | Buy |
| ADX (14) | 19.86 | Neutral |
| ATR (14) | 0.51 | Info |
The near-term technical picture is neutral, with a cautious outlook for the next 30 days. The RSI14 is 40, and price action sits around the moving averages, with the SMA50 at $23.33 and the SMA200 at $27.54. Support is identified at $22.45 and resistance at $26.84, underscoring a bounded trading range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $18.50 | $23.39 | $29.39 | 0% | Neutral | |
| $21.46 | $26.68 | $34.96 | +14% | Neutral | |
| $24.68 | $31.40 | $42.45 | +34% | Bullish | |
| $29.27 | $37.96 | $52.60 | +62% | Bullish | |
| $31.66 | $41.75 | $59.09 | +79% | Bullish | |
| $33.40 | $44.73 | $64.48 | +91% | Bullish | |
| $36.52 | $49.61 | $72.72 | +112% | Bullish | |
| $36.07 | $49.65 | $73.90 | +112% | Bullish | |
| $37.92 | $52.87 | $79.78 | +126% | Bullish | |
| $45.27 | $63.89 | $97.67 | +173% | Bullish | |
| $61.65 | $91.89 | $148.39 | +293% | Bullish | |
| $116.32 | $190.18 | $332.92 | +713% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $18.50 | $23.39 | $27.39 | +0.00% |
| June 2026 | $19.83 | $23.22 | $27.77 | -0.73% |
| July 2026 | $20.14 | $23.75 | $28.74 | +2.28% |
| August 2026 | $20.35 | $24.13 | $29.46 | +1.62% |
| September 2026 | $19.75 | $23.53 | $28.94 | -2.49% |
| October 2026 | $19.33 | $23.12 | $28.63 | -1.72% |
| November 2026 | $19.58 | $23.51 | $29.28 | +1.68% |
| December 2026 | $19.48 | $23.48 | $29.39 | -0.16% |
Click any year to see its month-by-month RARE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RARE is projected to trade between $18.50 and $29.39, averaging $23.39 — a potential gain of 0% from today's $23.39. A consolidation phase looks the most probable path here.
Ultragenyx Pharmaceutical Inc.'s 2027 outlook centres on $26.68, within a $21.46 to $34.96 range. That is up +14% on the projected 2026 average. That marks a +14% change versus current levels. Price action looks broadly range-bound.
By 2028, RARE could reach as high as $42.45, with a base case around $31.40 and support toward $24.68 — roughly +34% from $23.39. Buyers look set to stay in control over this stretch.
Expect RARE to range from $29.27 to $52.60 through 2029. The $37.96 average target implies a +62% move from current prices. That is up +21% on the projected 2028 average. Momentum favours further upside here.
The RARE price prediction for 2030 points to an average of $41.75 (low $31.66, high $59.09) — a potential gain of +79% on today's $23.39. Buyers look set to stay in control over this stretch.
In 2031, RARE is projected to trade between $33.40 and $64.48, averaging $44.73 — a potential gain of +91% from today's $23.39. That is up +7% on the projected 2030 average. Momentum favours further upside here.
Ultragenyx Pharmaceutical Inc.'s 2032 outlook centres on $49.61, within a $36.52 to $72.72 range. That is up +11% on the projected 2031 average. That marks a +112% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, RARE could reach as high as $73.90, with a base case around $49.65 and support toward $36.07 — roughly +112% from $23.39. Momentum favours further upside here.
Expect RARE to range from $37.92 to $79.78 through 2034. The $52.87 average target implies a +126% move from current prices. That is up +6% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The RARE price prediction for 2035 points to an average of $63.89 (low $45.27, high $97.67) — a potential gain of +173% on today's $23.39. Momentum favours further upside here.
In 2040, RARE is projected to trade between $61.65 and $148.39, averaging $91.89 — a potential gain of +293% from today's $23.39. That is up +44% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Ultragenyx Pharmaceutical Inc.'s 2050 outlook centres on $190.18, within a $116.32 to $332.92 range. That is up +107% on the projected 2040 average. That marks a +713% change versus current levels. Momentum favours further upside here.
Investing $1,000 in RARE today (≈ 42.753313 RARE) could be worth
$8,130.67
+$7,130.67 (+713%) by 2050 · US Dollar
Based on the average projected RARE price of $190.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RAREwould be worth at today's price.
$1,000 invested in RARE on May 27, 2025 (≈ 28.50627 RARE) would be worth
$666.76
-$333.24 (-33.3%) today · 0.67× · US Dollar
Based on a RARE entry price of $35.08 vs. today's $23.39.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $23.37 | $1,000.86 | +0.1% |
| 1 month ago | $23.99 | $974.99 | -2.5% |
| 3 months ago | $23.04 | $1,015.19 | +1.5% |
| 6 months ago | $34.75 | $673.09 | -32.7% |
| 1 year ago | $35.08 | $666.76 | -33.3% |
| All time (5.0y) ago | $99.83 | $234.3 | -76.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RARE forecast.
Our base-case forecast reaches $47.00 around 2032.
Implied market cap at $47.00: $4.63B
Long-term forecasts indicate a clear bullish path with rising averages and upside potential across the horizon. The 2026 average price is $23.39 with a min of $18.50 and a max of $29.21, and an ROI of 0%. From 2027 onward, the forecast shows growing upside, with a 2027 average of $26.46 and ROI of 13.1%, then accelerating through 2028 ($31.18, 33.3%), 2029 ($37.29, 59.5%), 2030 ($41.21, 76.2%), and continuing higher through 2031 ($44.15, 88.8%), 2032 ($48.34, 106.7%), 2033 ($48.29, 106.5%), 2034 ($51.38, 119.7%), and 2035 ($61.92, 164.8%.).
The bullish trend extends to 2040 ($88.86, 279.9%) and 2050 ($181.91, 677.7%), reflecting substantial long-horizon upside while acknowledging that these are estimates, not guarantees. The sentiment shifts from Neutral in 2026 to Bullish thereafter.
Tap a question to reveal the answer.
2030 forecast: average price $41.21 with a min of $30.99 and a max of $58.92; ROI 76.2%; sentiment Bullish.
The forecast shows a bullish long-term trajectory with rising average prices and higher ROIs after 2026, including 2030 average $41.21 and ROI 76.2%, but these are estimates, not guarantees.
The 2040 maximum is $145.74 and the 2050 maximum is $324.36, so a price of $100 could occur by 2040 or later years based on the forecast.
Current price is $23.39 and market cap is $2.3B.
2040 average is $88.86 with ROI 279.9% and a Bullish sentiment; 2050 average is $181.91 with ROI 677.7% and a Bullish sentiment.
Ultragenyx Pharmaceutical Inc. Community Discussion
0Share your Ultragenyx Pharmaceutical Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.